A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase of Trial: Phase III
Latest Information Update: 11 May 2016
At a glance
- Drugs Tedizolid (Primary) ; Tedizolid (Primary) ; Linezolid; Linezolid
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- Acronyms ABSSSI
- Sponsors Bayer
- 06 May 2016 Status changed from active, no longer recruiting to completed.
- 10 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 07 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.